All News

Fewer than 10% of patients are being told about the possibility of overdiagnosis and overtreatment as a result of screening for prostate and other cancers, according to findings from a recently published survey.

Men with short-ended chromosomes in the immune cells in their blood appear to be at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes, according to findings from a recent study.

The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.

A phase III trial of enzalutamide (Xtandi) in chemotherapy-naïve patients with advanced prostate cancer has met both of its primary endpoints in an interim analysis, and the trial will be stopped early due to the drug’s benefit.

The publication of data in the New England Journal of Medicine (2013; 369:1629-37) showing an increase in intensity-modulated radiation therapy utilization among self-referring urologists has reignited the self-referral controversy.

Many physicians continue to administer the PSA test to even their oldest patients despite the fact that no medical organization recommends routine prostate cancer screening in men older than 75 years of age, according to recently published research.

Researchers at the Duke Cancer Institute in Durham, NC say they have developed a tool to forecast the potential survival of individual prostate cancer patients, enabling physicians to better assess whether to try additional rounds of treatment or seek clinical trials.

In this interview, Dr. Samir S. Taneja discusses the AUA's recommendations on the optimal method to perform a prostate biopsy and handle specimens as well as how to minimize infection and the role of imaging.

Primary androgen deprivation therapy for localized prostate cancer is associated with significantly better survival outcomes in a Japanese cohort compared with an American population, according to a recent study.

Single-fraction radiotherapy for bone metastases from prostate cancer is not widely used despite its comparable efficacy and lower cost in relation to multiple-fraction treatment, according to a recent study.

Data from a phase II study suggest that the potency of sipuleucel-T (Provenge) and immunologic prime-boost responses are maintained when the immunotherapy is administered concurrently or sequentially with abiraterone acetate (ZYTIGA) plus prednisone.

In its push to close the loophole on physician self-referral for prostate cancer treatment, the American Society for Radiation Oncology now has what some may call an unlikely ally.

Abiraterone acetate (ZYTIGA) significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone, the authors of a multicenter study reported.

Short-term hormone therapy appears to produce outcomes that are as favorable as those for long-term therapy in men with intermediate-risk prostate cancer, according to the results of two studies from the Radiation Therapy Oncology Group.

Toxic chemicals in the environment harm our ability to reproduce and are associated with poor semen quality and prostate cancer, among other long-term health problems, according to the American College of Obstetricians and Gynecologists and the American Society for Reproductive Medicine.

The American Society for Radiation Oncology and the American Academy of Family Physicians have both released recommendations on the diagnosis and treatment of prostate cancer as part of the Choosing Wisely campaign.

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow growing, according to a recent study.

New research shows a significant decrease in PSA screening by primary care physicians since the release of the United States Preventive Services Task Force recommendation against screening in May 2012.

Outcomes following salvage radiation therapy after recurrent prostate cancer in a racially mixed cohort are no better when it’s started at a PSA level

Regular use of aspirin in the year before a diagnosis of stage I-III prostate cancer is associated with a reduction in prostate cancer-specific mortality, say Irish researchers.

African-American men are more influenced by convenience than are Caucasian men in their choice of treatment for early-stage prostate cancer, according to a recent study.

New therapies that are extending survival of men with metastatic castration-resistant prostate cancer may also be contributing to an increasing trend for the development of non-osseous metastatic disease in these patients, according to a recent study.

Researchers say a cooling device can reduce local inflammation and shorten time to continence-and even prevent permanent incontinence-in patients who undergo robot-assisted radical prostatectomy.

In an attempt to clarify what it calls conflicting guideline statements on prostate cancer screening from various organizations, the Large Urology Group Practice Association has issued its own position on the use of the PSA test as a screening tool.

In this case, the patient tried to keep the observing urologist in the case as another source of payment by claiming a physician-patient relationship existed, thus establishing he had a legal duty to ensure the care was within the accepted standard.

A recent study has linked genetic mutations to an increased risk of developing prostate cancer.

Even as the debate over the U.S. Preventive Services Task Force’s grade D recommendation for PSA screening continues, patients made their feelings clear about the recommendation in a recent survey.

Coffee consumption is associated with a lower risk of prostate cancer recurrence and progression, researchers reported.

For men aged 50–69 years, PSA testing reduces prostate cancer-specific mortality and the incidence of metastatic disease, according to a new multinational consensus statement on early detection of prostate cancer, which also calls for prostate cancer diagnosis to be unlinked from treatment for the disease.

Epigenetic profiling of prostate biopsies significantly improved the accuracy of predicting cancer in men with negative results, according to a late-breaking abstract presented at the AUA annual meeting in San Diego.